Will This Big Decision Knock the Biogen Roller Coaster Off the Tracks?

In 1906, Alois Alzheimer, a German doctor, first described the memory loss and psychological changes associated with the disease later named after him. A century later, it is the fifth leading cause of death among those over age 65. Although a few drugs have been developed to help patients manage the disease, nothing new has come to market since 2003.

Biogen (NASDAQ: BIIB) hopes that changes this week as the Food and Drug Administration (FDA) is set to rule on its application for aducanumab. The drug has shown some promise in clinical trials. However, many question its prospects after indecision from the company and mixed results in studies. The stock price has followed the ups and downs of the drug and taken shareholders for a ride. The decision is due by June 7th and could finally provide clarity as to how the company moves forward. 

Image source: Getty Images.

Continue reading

Source Fool.com